---
layout: default
title: Methoxy Polyethylene Glycol-Epoetin Beta
description: "Methoxy Polyethylene Glycol-Epoetin Beta drug repurposing predictions from TxGNN. Evidence level L5 with 50 predicted indications."
parent: AI Predictions (L5)
nav_order: 373
evidence_level: L5
indication_count: 50
---

# Methoxy Polyethylene Glycol-Epoetin Beta
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **50**
{: .fs-6 .fw-300 }

---

## Quick Overview

| Item | Value |
|------|-------|
| Drug Name | Methoxy Polyethylene Glycol-Epoetin Beta |
| DrugBank ID | [DB09107](https://go.drugbank.com/drugs/DB09107) |
| Brand Names (EU) | Mircera |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.36% |

---

## Approved Indication (EMA)

Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients (see section 5.1). Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA (see section 5.1).

---

## Predicted New Indications

TxGNN model predictions for potential drug repurposing:

| Rank | Indication | Score | Source |
|:----:|------------|------:|--------|
| 1 | primary release disorder of platelets | 99.36% | DL |
| 2 | Glanzmann thrombasthenia | 99.30% | DL |
| 3 | pseudo-von Willebrand disease | 99.25% | DL |
| 4 | severe nonproliferative diabetic retinopathy | 99.15% | DL |
| 5 | heparin cofactor 2 deficiency | 99.10% | DL |
| 6 | antithrombin deficiency type 2 | 99.07% | DL |
| 7 | factor 5 excess with spontaneous thrombosis | 99.04% | DL |
| 8 | thrombophilia | 98.91% | DL |
| 9 | diabetic retinopathy | 98.57% | DL |
| 10 | HER2 positive breast carcinoma | 98.45% | DL |
| 11 | plasma cell myeloma | 98.28% | DL |
| 12 | hemoglobinopathy | 98.11% | DL |
| 13 | fetal and neonatal alloimmune thrombocytopenia | 98.10% | DL |
| 14 | plasmacytoma | 98.03% | DL |
| 15 | seborrheic dermatitis | 97.91% | DL |
| 16 | indolent plasma cell myeloma | 97.85% | DL |
| 17 | psoriasis | 97.63% | DL |
| 18 | normal breast-like subtype of breast carcinoma | 97.57% | DL |
| 19 | progesterone-receptor positive breast cancer | 97.57% | DL |
| 20 | neurolymphomatosis | 97.56% | DL |

*Showing top 20 of 50 predictions.*

---

## About TxGNN Predictions

### Prediction Sources

| Source | Description |
|--------|-------------|
| **KG** | Knowledge Graph - Network topology-based associations |
| **DL** | Deep Learning - Neural network score prediction |

### Evidence Levels

| Level | Definition |
|:-----:|------------|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| **L5** | AI prediction only (current) |

---

## Clinical Validation Needed

<div style="background: #fff3cd; padding: 1rem; border-left: 4px solid #ffc107; border-radius: 4px; margin: 1rem 0;">
<strong>Research Use Only:</strong> These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
</div>

### Next Steps for Validation

1. **Literature Review**: Search PubMed for existing evidence
2. **Clinical Trial Search**: Check ClinicalTrials.gov for ongoing studies
3. **Mechanistic Analysis**: Evaluate biological plausibility
4. **Preclinical Studies**: Conduct in vitro/in vivo validation
5. **Clinical Trials**: Design and conduct human studies

---

## Data Access

- **FHIR API**: `/fhir/ClinicalUseDefinition/`
- **CSV Download**: [All Predictions](/downloads/)
- **GitHub**: [yao-care/EuTxGNN](https://github.com/yao-care/EuTxGNN)

---

## Citation

If using this data, please cite:

```bibtex
@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
```

---

<div style="background: #f8f9fa; padding: 1rem; border-radius: 4px; font-size: 0.9rem;">
<strong>Disclaimer:</strong> This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.
</div>
